Recalcitrant Alopecia Areata Responsive to Leflunomide and Anthralin—Potentially Undiscovered JAK/STAT Inhibitors?

October 2018 in “ Pediatric dermatology ”

Kabir Sardana, Aastha Gupta, R. K. Gautam

alopecia areata leflunomide anthralin JAK/STAT pathway JAK inhibitors steroid therapy ophiasis-pattern alopecia areata

Studysummary In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata

24 citations , January 2017 in “Pediatric dermatology”

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients

51 citations , June 2016 in “Journal of the European Academy of Dermatology and Venereology”

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

39 citations , April 2016 in “Case Reports in Dermatology”

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

research Alopecia Areata Secondary to the Use of Leflunomide in Patients with Rheumatoid Arthritis: A Case Report and Literature Review

6 citations , December 2015 in “Medwave”

This article presents a case of alopecia universalis linked to leflunomide use and reviews its application in rheumatoid arthritis treatment, highlighting potential adverse effects.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Alopecia Universalis During Treatment with Leflunomide and Adalimumab: Case Report

16 citations , April 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia”

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

research Vitiligo and Alopecia Areata: Apples and Oranges?

71 citations , October 2013 in “Experimental Dermatology”

This review discusses the similar immune pathways and genetic risk factors of vitiligo and alopecia areata but reports no new clinical findings, emphasizing the potential for shared treatment research.

research Alopecia Areata: Overview and Treatment Options

151 citations , February 2007 in “International Journal of Dermatology”

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.

research Restoration of Hair Growth in Mice with an Alopecia Areata-Like Disease Using Topical Anthralin

29 citations , January 2004 in “Experimental Dermatology”

In this study, anthralin treatment led to hair regrowth in alopecia areata-like affected C3H/HeJ mice, suggesting it may be an effective therapy for this condition.